medwireNews: Treatment with the antiangiogenesis inhibitor trebananib does not adversely affect health-related quality of life (HRQoL) in patients with recurrent ovarian cancer, suggests the placebo-controlled TRINOVA-1 trial.
Previously the randomised phase III trial showed significant improvements in progression-free survival and objective response rate with trebananib versus placebo, both given alongside paclitaxel, among women with recurrent disease.
In this analysis of patient-reported outcomes at 25 weeks, the average changes from baseline were “negligible” for the Functional Assessment of Cancer Therapy–Ovary, the ovarian cancer-specific subscale and the EuroQOL EQ-5D survey in both the trebananib (n=408) and placebo (n=426) arms.
Thus, the results show that the outcome improvements among patients in the trebananib arm “was achieved without compromising HRQoL”, conclude Keiichi Fujiwara, from Saitama Medical University International Medical in Japan, and study authors in the Annals of Oncology.
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016